Author: Kenneth Smith

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

In this series, we'll explore Thermo Fisher's financials and valuation, and analysts' views on its stock.

BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

In this series, we'll explore Abiomed's financials and valuation along with analysts' views on its stock.

In the third quarter, Sarepta's total revenue rose year-over-year to $78.49 million due to increasing demand for its drug Exondys 51.

Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.

In the third quarter, bluebird bio's total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

The Zulresso injection is Sage Therapeutics' lead product candidate. The company has filed a new drug application.

Ionis Pharmaceuticals' (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.

In the third quarter, DaVita's total revenue rose YoY (year-over-year) to $2.85 billion from $2.76 billion.

In the third quarter, Biogen's net product revenue rose year-over-year to $2.78 billion from $2.62 billion.